: The designated laboratories of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network have been integral to its success in defining the standards of care for HIV infected pregnant women, children and adolescents. IMPAACT laboratory studies have elucidated the pathogenesis of HIV transmission, improved strategies designed to interrupt mother-to-child transmission (MTCT), optimized HIV treatment even in the setting of multi-drug resistance, and enhanced the diagnosis, prevention and management of HIV-related complications. The laboratories have been leaders in the development and evaluation of assays for infant diagnosis, viral load monitoring, drug resistance, antiretroviral pharmacology, host genetics and the measurement of immune responses. These studies were performed within the constraints of the small blood volumes available from our study populations and internationally in resource-limited settings. Often new methodologies and novel approaches have been developed to accommodate the limited specimens available from infants, children and pregnant women. In addition, all laboratory studies were performed under a comprehensive Total Quality Management Program that assured the highest standards of laboratory testing. The IMPAACT Network Laboratory Center (LC) is led by Grace Aldrovandi MD, CM, who will work closely with the IMPAACT Leadership Group, the Laboratory Steering Committee and the External Advisory Board to support, synergize and enhance the IMPAACT scientific agenda. The LC has 2 overarching specific aims: (1) Provide laboratory-based scientific leadership, consultation and laboratory capacity, including the development and implementation of innovative assays and protocols to enhance IMPAACT's Research Agenda and seven scientific aims. (2) Provide the technical, regulatory and administrative infrastructure and oversight for all laboratory testing done in support of IMPAACT clinical trials.
The Laboratory Center will provide laboratory-based scientific leadership, consultation and laboratory capacity, to enhance IMPAACT's Research Agenda and achieve its Scientific Aims. It will also provide the technical, regulatory and administrative infrastructure ad oversight for all laboratory testing done in support of IMPAACT clinical trials.
|Duarte, Horacio A; Panpradist, Nuttada; Beck, Ingrid A et al. (2017) Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance. J Infect Dis 216:S824-S828|
|Wagner, Thor A; Huang, Hannah C; Salyer, Christen E et al. (2017) H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment did not induce measurable antigen-driven proliferation of the HIV-1 proviral reservoir. AIDS Res Ther 14:7|
|Levin, Myron J; Lindsey, Jane C; Kaplan, Susan S et al. (2017) Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS 31:49-59|
|Huo, Yanling; Patel, Kunjal; Scott, Gwendolyn B et al. (2017) Lymphocyte subsets in HIV-exposed uninfected infants and HIV-unexposed uninfected infants. J Allergy Clin Immunol 140:605-608.e3|
|Uprety, Priyanka; Lindsey, Jane C; Levin, Myron J et al. (2017) Inflammation and Immune Activation in Antiretroviral-Treated HIV-1-Infected African Infants and Rotavirus Vaccine Responses. J Infect Dis :|
|Walters, Elisabetta; van der Zalm, Marieke Magrieta; Palmer, Megan et al. (2017) Xpert MTB/RIF on Stool Is Useful for the Rapid Diagnosis of Tuberculosis in Young Children With Severe Pulmonary Disease. Pediatr Infect Dis J 36:837-843|
|Wolf, Elizabeth; Herbeck, Joshua T; Van Rompaey, Stephen et al. (2017) Short Communication: Phylogenetic Evidence of HIV-1 Transmission Between Adult and Adolescent Men Who Have Sex with Men. AIDS Res Hum Retroviruses 33:318-322|
|Levin, Myron J; Huang, Sharon; Moscicki, Anna-Barbara et al. (2017) Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine 35:1712-1720|
|Scott, Rachel K; Chakhtoura, Nahida; Burke, Margaret M et al. (2017) Delivery After 40 Weeks of Gestation in Pregnant Women With Well-Controlled Human Immunodeficiency Virus. Obstet Gynecol 130:502-510|
|Rainwater-Lovett, Kaitlin; Ziemniak, Carrie; Watson, Douglas et al. (2017) Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection. PLoS One 12:e0170548|
Showing the most recent 10 out of 80 publications